Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Anionic and Magnetic Ordering in Rare Earth Tantalum Oxynitrides with an n = 1 Ruddlesden-Popper Structure

  • Guarín, Jhonatan R.
  • Frontera, Carlos|||0000-0002-0091-4756
  • Oró-Solé, Judith|||0000-0002-3755-4950
  • Colombel, Bastian
  • Ritter, Clemens
  • Fauth, François|||0000-0001-9465-3106
  • Fontcuberta, Josep|||0000-0002-7955-2320
  • Fuertes, Amparo|||0000-0001-5338-9724
The new compounds RTaON with R = La, Ce, Nd, and Eu and 1.20 ≤ x ≤ 2.81 have been obtained by a solid-state reaction between metal nitrides and oxides or oxynitrides under N gas at temperatures between 1200 and 1700 °C. They are the first examples of rare earth transition metal oxynitrides with an n = 1 Ruddlesden-Popper structure and show different anion stoichiometries, crystal structures, and magnetic properties. Synchrotron X-ray powder diffraction and electron diffraction indicate that the lanthanum, cerium, and neodymium compounds crystallize in the orthorhombic space group Pccn, with cell parameters a = 5.72949(2), b = 5.73055(5), and c = 12.77917(6) Å for LaTaON, a = 5.70500(5), b = 5.71182(4), and c = 12.61280(7) Å for CeTaON, and a = 5.70466(3), b = 5.70476(5), and c = 12.32365(5) Å for NdTaON. In contrast, EuTaON shows a tetragonal I 4/ acd superstructure doubling the c axis, with parameters a = 5.71867(2) and c = 25.00092(19) Å. Refinement of neutron powder diffraction data of CeTaON indicated the nitrogen order in the two equatorial positions of the tantalum octahedron, with refined N/O occupancies of 0.930(7)/0.070 and 0.876(13)/0.124, and the axial position is occupied by 50% of each anion. This anion ordering agrees with the distribution predicted by Pauling's second crystal rule. Magnetization measurements show that the cerium and europium compounds are ordered magnetically at low temperatures, while the neodymium compound remains paramagnetic down to 2 K, as a consequence of suppression of the effective magnetic moment of the latter when reducing the temperature.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lithium halide filled carbon nanocapsules, Paving the way towards lithium neutron capture therapy (LiNCT)

  • Gonçalves, Gil|||0000-0002-2302-9661
  • Sandoval, Stefania|||0000-0002-0050-7501
  • Llenas, Marina|||0000-0002-1048-8869
  • Ballesteros, Belén|||0000-0002-1958-8911
  • Da Ros, Tatiana|||0000-0003-1932-1560
  • Bortolussi, Silva|||0000-0003-0452-2255
  • Cansolino, Laura|||0000-0002-8330-1532
  • Ferrari, Cinzia|||0000-0001-8356-7472
  • Postuma, Ian|||0000-0001-9678-9277
  • Protti, Nicoletta|||0000-0002-2415-128X
  • Melle-Franco, Manuel
  • Altieri, Saverio|||0000-0002-1376-3686
  • Tobias, Gerard|||0000-0001-7116-2152
Neutron capture therapy (NCT) is a form of radiotherapy that exploits the potential of some specific isotopes to capture thermal neutrons and subsequently yield high linear energy transfer (LET) particles, suitable for cancer treatment. Recently, relevant technological improvements have been made in terms of accelerators as suitable neutron sources for NCT at hospitals. However, low selective delivery of current drugs to cancer cells remains as the main challenge for successful clinical application of NCT. This work presents an innovative and previously unexplored approach for the design of nanotherapeutic NCT agents. Herein, a new concept based on carbon nanomaterials that seal Li active NCT nuclides is investigated. The Li active species are located in the inner cavity of the nanocarrier (carbon nanohorns or carbon nanotubes) and therefore, completely protected from the biological environment, avoiding toxicity and degradation. After encapsulation of the active cargo, the external surface of the nanocarrier is modified for improved biocompatibility. The developed Li-filled carbon nanohorns offered the possibility to explore Li compounds as active NCT agents by delivering therapeutic doses to cancer cells. We envisage that nanoencapsulation of Li can trigger the successful development and implementation of Lithium Neutron Cancer Therapy (LiNCT).